In the AVADO trial, biomarker analyses using plasma proteins, blood mRNA levels, immunohistochemistry of tumor tissue, and single-nucleotide polymorphisms of VEGF pathway-related genes in germline DNA were reported [10]. The gene discussed is VEGFA; the disease is neoplasm.